Peposertib
Nucleic acidexperimental
Clinical trial activity
9 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 25, 2017 (NCT03116971)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Renal Cell · Phase 1
- Colorectal Neoplasms · Phase 1/Phase 2
- Fibrosarcoma · Phase 1
- Healthy Volunteers · Phase 1
- Hypopharyngeal Neoplasms · Phase 1
- Laryngeal Neoplasms · Phase 1
- Leiomyosarcoma · Phase 1
- Liposarcoma · Phase 1
- Mouth Neoplasms · Phase 1
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 1
- Oropharyngeal Neoplasms · Phase 1
- Sarcoma · Phase 1
- Sarcoma, Synovial · Phase 1
- Small Cell Lung Carcinoma · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1
Mechanism of action
- DNA-dependent protein kinaseINHIBITOR
PRKDC inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- m3814
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05687136 | Phase 1 | Feb 25, 2024 | Harvard University, National Cancer Institute (NCI) |
| NCT05711615 | Phase 1 | Feb 2, 2024 | Harvard University, National Cancer Institute (NCI) |
| NCT05868174 | Phase 1 | May 23, 2023 | Merck KGaA, Telix |
| NCT04750954 | Phase 1 | Jun 4, 2021 | National Cancer Institute (NCI), Ohio State University |
| NCT04702698 | Phase 1 | Jan 14, 2021 | Merck KGaA |
| NCT04533750 | Phase 1 | Dec 10, 2020 | National Cancer Institute (NCI), NRG Oncology |
| NCT03770689 | Phase 1/Phase 2 (Phase 2) | Mar 20, 2019 | Merck KGaA, Merck Serono |
| NCT03724890 | Phase 1 | Nov 27, 2018 | Merck KGaA, Merck Serono |
| NCT03116971 | Phase 1/Phase 2 (Phase 2) | May 25, 2017 | Merck KGaA, Merck Serono |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck KGaA | For profit | 5 | 1 | 2 | 2017 |
| National Cancer Institute (NCI) | Government | 4 | 4 | 1 | 2020 |
| Merck Serono | For profit | 3 | 3 | 2 | 2017 |
| Harvard University | Academic/Hospital | 2 | 0 | 1 | 2024 |
| NRG Oncology | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Telix | For profit | 1 | 1 | 1 | 2023 |
7 organizations
Page 1 / 1